The non-dihydropyridine calcium channel blockers have antiarrhythmic effects, and its representative drugs are diltiazem and verapamil. Diltiazem can reduce the autoregulation and conduction of sinus node and atrioventricular node, and can be used to treat supraventricular tachyarrhythmias in clinical practice. Verapamil, when given orally, can control ventricular rate in patients with atrial flutter and atrial fibrillation and can prevent paroxysmal supraventricular tachycardia. If administered intravenously, it can revert paroxysmal supraventricular tachycardia and branching ventricular tachycardia, and can slow down the rapid ventricular rate in atrial fibrillation and atrial flutter. In addition to treating arrhythmias, it can also treat angina pectoris and has a beneficial effect on patients with hypertrophic cardiomyopathy.